Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds

by

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and extended the lifespan of people with this degenerative disorder.

Leave A Comment

Your email address will not be published. Required fields are marked *